Involvement of p53 in oroxylin A-induced apoptosis in cancer cells

Molecular Carcinogenesis

Volumn 48, Issue 12, 2009, Pages 1159-1169

  Mu, Rong ^a   Qi, Qi ^a   Gu, Hongyan ^a   Wang, Jia ^a   Yang, Yong ^a   Rong, Jingjing ^a   Liu, Wei ^a   Lu, Na ^a   You, Qidong ^a   Guo, Qinglong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cancer; Oroxylin A; p53

Indexed keywords

ACETYLCYSTEINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLOHEXIMIDE; MESSENGER RNA; OROXYLIN A; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; ANTIOXIDANT; FLAVONOID; MDM2 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL STRAIN HEPG2; CELL STRAIN K 562; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MESSENGER RNA SYNTHESIS; NULL ALLELE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WILD TYPE; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCUTELLARIA BAICALENSIS; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

SCUTELLARIA RADIX;

ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; BLOTTING, WESTERN; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FLAVONOIDS; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SCUTELLARIA BAICALENSIS; TUMOR SUPPRESSOR PROTEIN P53; UMBILICAL VEINS;

EID: 73349102814     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20570     Document Type: Article

References (46)

1. Kim YH, Jeong DW, Paek IB, et al. Liquid chromatography with tandem mass spectrometry for the simultaneous determination of baicalein, baicalin, oroxylin A andwogonin in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2006;844:261-267.
2. Chen Y, Yang L, Lee TJ. Oroxylin A inhibition of lipopolysaccharide- induced iNOS and COX-2 gene expression via suppression of nuclear factor-kappaB activation. Biochem Pharmacol 2000;59:1445-1457.
3. Hu Y, Yang Y, You QD, et al. Oroxylin A induced apoptosis of human hepatocellular carcinoma cell line HepG2 was involved in its antitumor activity. Biochem Biophys Res Commun 2006;351:521-527.
4. Yang Y, Hu Y, Gu HY, et al. Oroxylin A induces G(2)/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells. J Pharm Pharmacol 2008;60:1459-1463.
5. Li HN, Nie FF, Liu W, et al. Apoptosis induction of oroxylin A in human cervical cancer HeLa cell line in vitro and in vivo. Toxicology 2009;257:80-85.
6. Hietanen S, Lain S, Krausz E, Blattner C, Lane DP. Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA 2000;97:8501-8506.
7. Teodoro JG, Parker AE, Zhu X, Green MR. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 2006;313:968-971.
8. Giono LE, Manfredi JJ. The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 2006;209:13-20.
9. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998;8:345-357.
10. Schmid G, Kramer MP, Maurer M, Wandl S, Wesierska-Gadek J. Cellular and organismal ageing: Role of the p53 tumor suppressor protein in the induction of transient and terminal senescence. J Cell Biochem 2007;101:1355-1369.
11. Roger L, Gadea G, Roux P. Control of cell migration: A tumour suppressor function for p53? Biol Cell 2006;98:141-152.
12. Green DR, Chipuk JE. p53 and metabolism: Inside the TIGAR. Cell 2006;126:30-32.
13. Bensaad K, Vousden KH. p53: New roles in metabolism. Trends Cell Biol 2007;17:286-291.
14. Semenza GL. VHL and p53: Tumor suppressors team up to prevent cancer. Mol Cell 2006;22:437-439.
15. Crighton D, Wilkinson S, O'Prey J, et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006;126:121-134.
16. Tasdemir E, Maiuri MC, Orhon I, et al. p53 represses autophagy in a cell cycle-dependent fashion. Cell Cycle 2008;7:3006-3011.
17. Lane DP, Lain S. Therapeutic exploitation of the p53 pathway. Trends Mol Med 2002;8:S38-S42.
18. Bell HS, Ryan KM. Targeting the p53 family for cancer therapy: 'Big brother' joins the fight. Cell Cycle 2007;6:1995-2000.
19. Yu Q. Restoring p53-mediated apoptosis in cancer cells: New opportunities for cancer therapy. Drug Resist Update 2006;9:19-25.
20. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006;21:307-315.
21. Erster S, Mihara M, Kim RH, Petrenko O, Moll UM. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 2004;24:6728-6741.
22. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res 2003;1:993-1000.
23. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Monoversus polyubiquitination: Differential control of p53 fate by Mdm2. Science 2003;302:1972-1975.
24. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003;13:49-58.
25. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-310.
26. Scovassi AI, Poirier GG. Poly(ADP-ribosylation) and apoptosis. Mol Cell Biochem 1999;199:125-137.
27. Inoue T, Geyer RK, Yu ZK, Maki CG. Downregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents. FEBS Lett 2001;490:196-201.
28. Yee KS, Vousden KH. Complicating the complexity of p53. Carcinogenesis 2005;26:1317-1322.
29. Honda R, Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 2000;19:1473-1476.
30. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000;275:8945-8951.
31. Harris SL, Levine AJ. The p53 pathway: Positive and negative feedback loops. Oncogene 2005;24:2899-2908.
32. Bouchet BP, de Fromentel CC, Puisieux A, Galmarini CM. p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol 2006;58:190-207.
33. Silva J, Silva JM, Dominguez G, et al. Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J Pathol 2003;199:289-297.
34. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res 2003;1:1001-1008.
35. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999;1:20-26.
36. Lin J, Zhu MH. Interactive pathway of ARF-mdm2-p53. Ai Zheng 2003;22:328-330.
37. Fisher DE. Turning p53 on or off: Either way may treat cancer. Drug Resist Update 2000;3:77-79.
38. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853-6866.
39. Gilmore TD, Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 2006;25:6887-6899.
40. Dey A, Tergaonkar V, Lane DP. Double-edged swords as cancer therapeutics: Simultaneously targeting p53 and NFkappaB pathways. Nat Rev Drug Discov 2008;7:1031-1040.
41. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I. p53 stabilization is decreased upon NFkappaB activation: A role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 2002;1:493-503.
42. Liu B, Chen Y, St Clair DK. ROS and p53: A versatile partnership. Free Radic Biol Med 2008;44:1529-1535.
43. Liu W, Mu R, Nie FF, et al. MAC related mitochondrial pathway in oroxylin A induces apoptosis in human hepatocellular carcinoma HepG2 cells. Cancer Lett 2009; DOI:10.1016/j.canlet.2009.04.021.
44. Matlashewski G, Banks L, Pim D, Crawford L. Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur J Biochem 1986;154:665-672.
45. Benchimol S, Pim D, Crawford L. Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. EMBO J 1982;1:1055-1062.
46. Hwang ES, Naeger LK, DiMaio D. Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene. Oncogene 1996;12:795-803.